Value creation and sharing among universities, biotechnology and pharma

Edwards, Mark G; Murray, Fiona; Yu, Robert
June 2003
Nature Biotechnology;Jun2003, Vol. 21 Issue 6, p618
Academic Journal
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.


Related Articles

  • Gold in the ivory tower: equity rewards of outlicensing. Edwards, Mark; Murray, Fiona; Yu, Robert // Nature Biotechnology;May2006, Vol. 24 Issue 5, p509 

    The article focuses on issues and topics regarding university-biotech licensing agreements in the U.S. Over time, university-biotech licensing agreements have become more complex as biotech companies increasingly relied upon academic discoveries a the foundation of their technology value....

  • A biokiller HVAC system.  // Machine Design;7/24/2003, Vol. 75 Issue 14, p23 

    Reports on the decision of The Bio-Defense Research Group Inc. of Upper Marlboro, Maryland to license a pathogen-neutralization technology developed by the Johns Hopkins University Applied Physics Lab of Laurel, Maryland. Mechanism of the Safe Building technology; Applications of the technology.

  • Introduction.  // Pharmaceutical Research & Development Productivity - The Paradig;2007, p3 

    The article focuses on the trends in licensing in the pharmaceutical industry from 1197 to 2006. It notes the number of licensing deals for clinical stage products which continues to increase and the group of players in the licensing game such as universities in which the value of deals is much...

  • Alteris licenses rights for cancer vaccine.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p17 

    Reports on the license agreement between Alteris Therapeutics Inc. and Duke University and john Hopkins University for the rights of cancer vaccine. Terms of the deal; Benefits of the agreement for parties involved; Significance of the agreement for the development of cancer vaccine.

  • Commercial knowledge transfers from universities to firms: improving the effectiveness of university�industry collaboration. Siegel, Donald S.; Waldman, David A.; Atwater, Leanne E.; Link, Albert N. // Journal of High Technology Management Research;Spring2003, Vol. 14 Issue 1, p111 

    There has been a rapid rise in commercial knowledge transfers from universities to practitioners or university�industry technology transfer (UITT), through licensing agreements, research joint ventures, and start-ups. The purpose of this study was to analyze the UITT process and its...

  • U. of Akron research draws licensing deal. Robinson, Ruthann // Crain's Cleveland Business;5/13/2002, Vol. 23 Issue 19, p5 

    Reports the license agreement between CathNet-Science and the University of Akron Research Foundation for the nitric oxide-releasing compound. Biotechnology to help speed the healing process among heart patients; Terms of the agreement; Number of technology-transfer licensing agreement...

  • PSMA LICENSES ALPHAVAX ARV FOR PROSTATE CANCER VACCINE.  // Biotech Business;Oct2001, Vol. 14 Issue 10, p1 

    Reports the licensing agreement between PSMA Development Co. LLC, Cytogen Corp. and AlphaVax Human Vaccines Inc. for the creation of a prostate cancer vaccine using the AlphaVax Replicon Vector system.

  • A Pilot Survey on the Licensing of DNA Inventions. Henry, Michelle R.; Cho, Mildred K.; Weaver, Meredith A.; Merz, Jon F. // Journal of Law, Medicine & Ethics;Fall2003, Vol. 31 Issue 3, p442 

    Reports on the results of pilot survey on licensing of DNA interventions. Patenting strategies; Licensing practices; Difficult issues in licensing negotiations.

  • Value drivers in licensing deals. Arnold, Katie; Coia, Anthony; Saywell, Scott; Smith, Ty; Minick, Scott; Löffler, Alicia // Nature Biotechnology;Nov2002, Vol. 20 Issue 11, p1085 

    Determines the appropriate gauge on how the value of licensing deals in commercial biotechnology is identified, enhanced and captured. Three quantitative methods used to analyze biotechnology products; Value of product deals between biotechnology and pharmaceutical companies; Impact of the type...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics